the epidermal growth factor egfr family

Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity.

Dacomitinib hydrate (PF 299804) is a highly selective and second-generation small-molecule inhibitor of the pan-epidermal growth factor receptor family of tyrosine kinases. Dacomitinib specifically and irreversibly binds to and inhibits human EGFR subtypes, resulting in inhibition of proliferation and induction of apoptosis in EGFR-expressing tumor cells.

MTX-211, an inhibitor of EGFR and PI3K, is used for the therapy of cancer and other diseases.

Afatinib N-Oxide, an impurity resulting from the oxidative degradation of Afatinib, is an irreversible inhibitor of the EGFR (Epidermal Growth Factor Receptor) family.

Pirotinib is an orally available inhibitor targeting the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, exhibiting potential antineoplastic activity.

Epidermal Growth Factor Receptor Peptide Acetate exists on the cell surface and is activated by the binding of its specific ligands.EGFR belongs to the ErbB family of receptor tyrosine kinases (RTK).